The FDA approved AMX0035 (Relyvrio) for amyotrophic lateral sclerosis (ALS) Thursday; new research suggests looking at microbes and fungi within cancer tumors; US suicides increased in 2021 following a 2-year decrease in deaths by suicide.
The FDA approved experimental drug AMX0035 (Relyvrio) for amyotrophic lateral sclerosis (ALS) Thursday, The Washington Post reported. AMX0035 was developed to slow the effects of ALS by protecting nerve cells in the brain and spinal cord damaged by the neurological condition. The approval was granted despite it being a much-debated drug with questions about its efficacy. However, some individuals living with ALS said a treatment with any amount of efficacy is important, as this was the first approval for an ALS treatment in 5 years.
New research suggested looking at microbes and fungi within cancer tumors rather than treating tumors as if they are sterile, The New York Times reported. A team of researchers detected bacteria living in pancreatic tumors in 2017, prompting further research on how a species of bacteria could block a chemotherapy drug from working and later finding bacteria in tumors of 7 types of cancer. Using these findings, another team of researchers found that a small percentage of DNA fragments in 32 types of cancer belonged to bacteria rather than humans. The 2 research teams collaborated and found that, in 35 different types of cancer, all of them contained fungi and each had a distinctive combination of fungal species.
Following a 2-year decrease in suicides in 2019 and 2020, US suicides have risen again, with experts saying rates are returning to prepandemic levels, The Wall Street Journal reported. This finding is based on data from the National Center for Health Statistics. The report stated 47,646 Americans died by suicide in 2021, reflecting a nearly 4% increase compared with the still high count of 45,979 deaths by suicide in 2020. It also said men aged between 15 and 24 years experienced the sharpest increase with an 8% rise in 2021. Notably, despite the onset of the COVID-19 pandemic, suicide rates did not markedly increase in 2020.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More